Oh god seriously , you have to do more research your toxic...

Oh god seriously , you have to do more research your toxic therapy company CEO is much more informed than you sheeps

Boosting Immune Response: Pembrolizumab is a PD-1 inhibitor, a type of immune checkpoint inhibitor. Tumors can evade the immune system by exploiting the PD-1 pathway, which suppresses T-cell activity. By blocking this pathway, pembrolizumab allows the immune system to remain active against cancer cells. When used with Her-Vaxx, which triggers an antibody response targeting HER2, pembrolizumab further amplifies the immune response by enabling T-cells to attack the tumor more effectively

Overcoming Resistance: In many cases, tumors develop resistance to treatments like trastuzumab (another HER2-targeting therapy), and Her-Vaxx alone might not be sufficient to overcome this. The combination with pembrolizumab helps the immune system overcome this resistance by attacking the cancer from different angles: Her-Vaxx targets the HER2 receptor, while pembrolizumab releases the brakes on immune cells

Synergistic Effects: Preclinical data suggest that combining vaccine-based therapies like Her-Vaxx with checkpoint inhibitors like pembrolizumab produces a synergistic effect. This means that the two drugs together are more effective than either one alone, leading to better outcomes like longer progression-free survival and overall survival

just read through the peer reviewed article if you have the acumen

https://aacrjournals.org/clincancerres/article/27/13/3649/671490/Clinical-and-Immunologic-Responses-to-a-B-Cell